Información de Schrodinger Inc, dividendo de Schrodinger Inc, actividades de los accionistas y más

Más Datos de Schrodinger Inc Compañía

Schrodinger, Inc. operates a physics-based computational platform that enables the discovery of molecules for drug development and materials applications. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. The Company operates through two segments: Software and Drug Discovery. The Software segment is focused on selling its software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment is focused on building a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The Company's pipeline of drug discovery programs includes SGR-1505 (MALT1 Inhibitor), SGR-2921 (CDC7 Inhibitor), SGR-3515 (WEE1 Inhibitor). Its software was used by researchers around the world at more than 1,760 academic institutions.

Información de Schrodinger Inc



Símbolo de cotizaciónSDGR

Nombre de la empresaSchrodinger Inc

Fecha de salida a bolsaFeb 06, 2020

Director ejecutivoDr. Ramy Farid, Ph.D.

Número de empleados891

Tipo de seguridadOrdinary Share

Fin del año fiscalFeb 06

Dirección1540 Broadway

CiudadNEW YORK

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal10036

Teléfono15032991150

Sitio Webhttps://www.schrodinger.com

Símbolo de cotizaciónSDGR

Fecha de salida a bolsaFeb 06, 2020

Director ejecutivoDr. Ramy Farid, Ph.D.

Ejecutivos de Schrodinger Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.37%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Michael M. Lynton ,

Independent Chairman of the Board

12.25K

+95.95%

Ms. Bridget Anne Van Kralingen

Independent Director

11.50K

+14.99%

Mr. Mannix Aklian

Executive Vice President, Chief Commercial Officer, Global Head of Software Sales & Marketing

--

Mr. Gary Ginsberg, J.D.

Independent Director

--

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. Richard A. Friesner, Ph.D.

Director

1.24M

+0.49%

Mr. Kenneth Patrick (Patrick) Lorton

Executive Vice President, Chief Operating Officer - Software

36.99K

-30.96%

Ms. Margaret Dugan, M.D.

Chief Medical Officer

24.57K

-5.37%

Ms. Yvonne Tran, J.D.

Chief People Officer, Executive Vice President, Chief Legal Officer

23.64K

+112.26%

Mr. Arun Oberoi

Independent Director

12.25K

+95.95%

Dr. Rosana Kapeller-Libermann, M.D., Ph.D.

Independent Director

12.25K

+95.95%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

On-premise software

15.74M

28.75%

Drug discovery services

13.94M

25.46%

Hosted software

11.13M

20.32%

Software maintenance

6.78M

12.38%

Contribution

4.51M

8.24%

Otro

2.66M

4.85%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

34.05M

62.18%

EMEA

13.56M

24.77%

APAC

6.97M

12.73%

Rest of World

175.00K

0.32%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

On-premise software

15.74M

28.75%

Drug discovery services

13.94M

25.46%

Hosted software

11.13M

20.32%

Software maintenance

6.78M

12.38%

Contribution

4.51M

8.24%

Otro

2.66M

4.85%

Estadísticas de accionistas

Actualizado: sáb., 1 de nov

Accionistas

Tipos de accionistas

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

12.66%

Bill & Melinda Gates Foundation Trust

10.82%

The Vanguard Group, Inc.

9.81%

Rubric Capital Management LP

7.75%

Amova Asset Management Co., Ltd.

7.06%

Otro

51.89%

Accionistas

Proporción

BlackRock Institutional Trust Company, N.A.

12.66%

Bill & Melinda Gates Foundation Trust

10.82%

The Vanguard Group, Inc.

9.81%

Rubric Capital Management LP

7.75%

Amova Asset Management Co., Ltd.

7.06%

Otro

51.89%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

46.69%

Investment Advisor/Hedge Fund

29.18%

Hedge Fund

19.49%

Endowment Fund

10.82%

Individual Investor

2.64%

Research Firm

2.60%

Bank and Trust

1.72%

Pension Fund

0.91%

Venture Capital

0.13%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

545

71.77M

111.28%

-2.08M

2025Q2

572

66.46M

103.14%

-5.60M

2025Q1

593

67.21M

104.69%

-5.43M

2024Q4

576

64.44M

100.89%

-9.04M

2024Q3

581

67.44M

105.91%

-6.15M

2024Q2

573

64.76M

101.80%

-8.12M

2024Q1

574

63.48M

100.05%

-5.40M

2023Q4

584

62.06M

98.56%

-7.64M

2023Q3

586

63.62M

101.35%

-15.42M

2023Q2

584

64.04M

102.20%

-7.30M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

BlackRock Institutional Trust Company, N.A.

8.17M

12.68%

+419.13K

+5.41%

Jun 30, 2025

Bill & Melinda Gates Foundation Trust

6.98M

10.83%

--

Jun 30, 2025

The Vanguard Group, Inc.

6.60M

10.25%

+74.93K

+1.15%

Jun 30, 2025

Rubric Capital Management LP

5.00M

7.76%

+200.00K

+4.17%

Jun 30, 2025

Amova Asset Management Co., Ltd.

3.65M

5.66%

+187.53K

+5.42%

Jun 30, 2025

Cadian Capital Management LP

3.05M

4.73%

+1.94M

+175.65%

Jun 30, 2025

Stephens Investment Management Group, LLC

2.26M

3.51%

+291.39K

+14.79%

Jun 30, 2025

State Street Investment Management (US)

2.19M

3.39%

-26.19K

-1.18%

Jun 30, 2025

MFS Investment Management

1.49M

2.32%

-598.55K

-28.60%

Jun 30, 2025

ARK Investment Management LLC

1.96M

3.04%

-335.26K

-14.61%

Jun 30, 2025

ETFs relacionados



Actualizado: jue., 6 de nov

Nombre

Proporción

ARK Genomic Revolution ETF

3.29%

TrueShares Technology, AI & Deep Learning ETF

1.87%

Global X HealthTech ETF

1.47%

SPDR FactSet Innovative Technology ETF

0.99%

Franklin Exponential Data ETF

0.82%

WisdomTree BioRevolution Fund

0.75%

Invesco S&P SmallCap Health Care ETF

0.71%

Franklin Genomic Advancements ETF

0.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

0.45%

First Trust Multi-Manager Small Cap Opportunities ETF

0.43%

ARK Genomic Revolution ETF

Proporción3.29%

TrueShares Technology, AI & Deep Learning ETF

Proporción1.87%

Global X HealthTech ETF

Proporción1.47%

SPDR FactSet Innovative Technology ETF

Proporción0.99%

Franklin Exponential Data ETF

Proporción0.82%

WisdomTree BioRevolution Fund

Proporción0.75%

Invesco S&P SmallCap Health Care ETF

Proporción0.71%

Franklin Genomic Advancements ETF

Proporción0.47%

First Trust Nasdaq Lux Digi Health Solutions ETF

Proporción0.45%

First Trust Multi-Manager Small Cap Opportunities ETF

Proporción0.43%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos